View More Recent Stories

Mar 29, 2022 05:00PM Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
Mar 25, 2022 07:00AM Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
Mar 11, 2022 07:02AM Castle Biosciences Inc. (CSTL) Reports Independent Data Demonstrated DecisionDx-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
Mar 11, 2022 07:00AM Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
Mar 1, 2022 07:00AM Castle Biosciences to Present at Upcoming Investor Conferences
Feb 28, 2022 04:05PM Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results
Feb 14, 2022 07:00AM Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
Feb 7, 2022 07:00AM Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 3, 2022 07:00AM Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
Feb 2, 2022 07:00AM Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
Jan 24, 2022 07:00AM Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
Jan 13, 2022 05:00PM Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
Jan 12, 2022 07:00AM Castle Biosciences Inc. (CSTL) Reports Publication Demonstrating Highly Accurate Performance of DecisionDx-UMSeq for Patients with Uveal Melanoma
Jan 12, 2022 07:00AM Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
Jan 10, 2022 07:12AM Castle Biosciences Inc. (CSTL) Announces Preliminary Fourth Quarter and Full-Year 2021 Results
Jan 10, 2022 07:00AM Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
Dec 28, 2021 07:00AM Castle Biosciences to Present at the 24th Annual Needham Growth Conference
Dec 6, 2021 07:00AM Castle Biosciences Completes Acquisition of Cernostics
Aug 2, 2021 07:00AM Castle Biosciences Collaborates with the Melanoma Research Foundation
Apr 30, 2021 07:00AM Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
View More Recent Stories